Imaging the dopamine D 3 receptor (D 3 R) in humans in vivo has been hampered by the lack of suitable tools. The D 3 R is pharmacologically similar to the dopamine D 2 receptor (D 2 R), and is located in the same brain areas as the D 2 R, albeit at significantly lower density. The signal obtained from a positron emission tomography (PET) study is proportional to the target density (B avail ) and the affinity of the PET radioligand for the target (K d limitation of injected mass of (+)-PHNO to <3 mg virtually eliminates the incidence of nausea. The occurrence of nausea in a significant proportion of healthy volunteers and the high affinity of (+)-PHNO for D 3 R (Gallezot et al. 2009 ), lead to the conclusion that (+)-PHNO occupies a significant proportion of D 3 R during a baseline scan. Using estimates from primate studies, and the limited human data available we estimate that injected masses <0.5 mg may be needed to achieve (+)-PHNO occupancies <10 %. Due to the nature of the radiochemistry methods involved in labelling (+)-PHNO with 11 C, the sufficiently high specific activity necessary to achieve this may not be feasible. Therefore, studies quantifying D 3 R status need to account for the occupancy of D 3 R by (+)-PHNO during the baseline scan.
Imaging the dopamine D 3 receptor (D 3 R) in humans in vivo has been hampered by the lack of suitable tools. The D 3 R is pharmacologically similar to the dopamine D 2 receptor (D 2 R), and is located in the same brain areas as the D 2 R, albeit at significantly lower density. The signal obtained from a positron emission tomography (PET) study is proportional to the target density (B avail ) and the affinity of the PET radioligand for the target (K d (Narendran et al. 2006 ; Rabiner et al. 2009 ). As the relative density of D 2 R in most brain regions is significantly higher than that of D 3 R, the y20-fold selectivity of Two other practical considerations need to be considered when imaging with [
11 C](+)-PHNO. The relatively high levels of D 3 R occupancy achieved even at tracer doses administered during PET scans (Gallezot et al. 2009) , and the reported incidence of nausea in human subjects in the first 10 min after injection of (Mizrahi et al. 2009 ), are both consistent with its high affinity and agonist properties. Nausea, a well recognized side-effect of D 2 /D 3 agonists (Osinski et al. 2005) , is observed in a significant proportion of subjects ; however, limitation of the injected mass to <0.03 mg/kg eliminates the vast majority of these effects (Mizrahi et al. 2009 ). Our experience is very consistent with that of Mizrahi et al.; limitation of injected mass of (+)-PHNO to <3 mg virtually eliminates the incidence of nausea. The occurrence of nausea in a significant proportion of healthy volunteers and the high affinity of (+)-PHNO for D 3 R (Gallezot et al. 2009 ), lead to the conclusion that (+)-PHNO occupies a significant proportion of D 3 R during a baseline scan. Using estimates from primate studies, and the limited human data available we estimate that injected masses <0.5 mg may be needed to achieve (+)-PHNO occupancies <10 %. Due to the nature of the radiochemistry methods involved in labelling (+)-PHNO with 11 C, the sufficiently high specific activity necessary to achieve this may not be feasible. Therefore, studies quantifying D 3 R status need to account for the occupancy of D 3 R by (+)-PHNO during the baseline scan.
Despite these challenges, [ 11 C](+)-PHNO PET remains the only feasible method to examine the interaction of centrally active compounds with D 3 R, or the status of D 3 R in various pathological conditions. Practically, the dissection of D 3 R and D 2 R components of [
11 C](+)-PHNO, requires an ability to block one of the sites with a selective blocker, such as SB-277011, with a selectivity of at least 100-fold and suitable for use in humans.
The paper by Graff-Guerrero and colleagues (2009) evaluates in humans in vivo, the occupancy of [
11 C](+)-PHNO binding sites by ABT-925, a compound with 45-to 120-fold selectivity for D 3 R over D 2 R in vitro. A selectivity of this magnitude would enable the use of ABT-925 in conjunction with [
11 C](+)-PHNO to study D 3 R. Although it has been generally recognized that the absolute in-vitro affinity can differ significantly from the one in vivo, the in-vitro ratio of affinities of a compound for two sites has been considered to be a good representation of the in-vivo situation. It is, however, important to confirm in-vivo affinity ratios derived from in-vitro assays, as differences between the two were found previously for other systems (Ekelund et al. 2007 ; Slifstein et al. 2007 ).
The authors undertake such an examination via an approach previously employed for SB-277011 in nonhuman primates (Rabiner et al. 2009 ), allowing the estimation of an in-vivo affinity of ABT-925 for D 2 R and D 3 R in humans. Unfortunately in vivo, ABT-925 demonstrates at best a 2-to 4-fold higher affinity for D 3 R over D 2 R, which does not reach statistical significance. Thus it would be more accurate for the title to refer to ABT-925 as a D 2 /D 3 rather than a D 3 receptor antagonist, consistent with its profile in the human brain in vivo. The paper by Graff-Guerrero et al. (2009) is an important demonstration of the need for early evaluation of in-vivo affinity of a compound in development. While ABT-925 may have utility as a novel pharmaceutical, its lack of selectivity for D 3 R in vivo makes it unsuitable for use as a selective antagonist alongside [
11 C](+)-PHNO to image D 3 R. Evaluation of D 3 R status in humans awaits truly selective D 3 R antagonists.
